Clinical Trial Detail

NCT ID NCT03581292
Title Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors National Cancer Institute (NCI)
Indications

glioblastoma multiforme

malignant glioma

grade III astrocytoma

Therapies

Temozolomide + Veliparib

Veliparib

Age Groups: child adult

Additional content available in CKB BOOST